Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)

China flag China · Delayed Price · Currency is CNY
5.25
-0.18 (-3.31%)
Jun 8, 2026, 3:04 PM CST
Market Cap3.30B -1.4%
Revenue (ttm)661.41M -13.7%
Net Income-106.43M
EPS-0.17
Shares Out 627.62M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,340,457
Open5.35
Previous Close5.43
Day's Range5.19 - 5.42
52-Week Range5.19 - 10.07
Beta0.47
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About SHE:300639

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/i... [Read more]

Sector Healthcare
Founded 2003
Employees 2,205
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300639
Full Company Profile

Financial Performance

In 2025, SHE:300639's revenue was 669.64 million, a decrease of -17.89% compared to the previous year's 815.53 million. Losses were -130.94 million, -80.01% less than in 2024.

Financial Statements